International Journal of Hematology and Oncology
2023, Vol 33, Num 3 (Special Issue) Page(s): 010-017
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Long-term Treatment of Chronic Myeloid Leukemia
Akif Selim YAVUZ
Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul, TURKEY
Keywords: Chronic myeloid leukemia, Long term treatment, Monitorization
Imatinib, a selective tyrosine kinases inhibitor (TKI), has excellent efficacy in the treatment of chronic myeloid leukemia (CML). Imatinib resistance and intolerance opened the way to the development of second generation TKIs against CML, including nilotinib and dasatinib. Because all TKIs are more effective drugs in comparison with previous therapies in CML, the followup period is now longer in the TKI era. These compounds are prescribed for prolonged periods, often in patients with comorbidities. Therefore, monitoring of CML should comprise the response to TKIs and long term effects of the TKIs.
Akif Selim YAVUZ
Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul, TURKEY
Keywords: Chronic myeloid leukemia, Long term treatment, Monitorization
Imatinib, a selective tyrosine kinases inhibitor (TKI), has excellent efficacy in the treatment of chronic myeloid leukemia (CML). Imatinib resistance and intolerance opened the way to the development of second generation TKIs against CML, including nilotinib and dasatinib. Because all TKIs are more effective drugs in comparison with previous therapies in CML, the followup period is now longer in the TKI era. These compounds are prescribed for prolonged periods, often in patients with comorbidities. Therefore, monitoring of CML should comprise the response to TKIs and long term effects of the TKIs.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |